Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Drug Design, Development and Therapy is Scopus-indexed (Q1, CiteScore 6.9), WoS SCIE, DOAJ. Published by Dove Medical Press Ltd.
Checked against the index lists dated .
ISSN 1177-8881Verify ISSN ↗
Publisher: Dove Medical Press Ltd
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmaceutical Science | 47 / 191 | 75th | Q1 |
| Pharmacology | 81 / 328 | 75th | Q1 |
| Drug Discovery | 46 / 161 | 71st | Q2 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2007–present, best quartile Q1, CiteScore 6.9.
Drug Design, Development and Therapy is Q1 in Pharmaceutical Science (rank 47 of 191), Q1 in Pharmacology (rank 81 of 328) and Q2 in Drug Discovery (rank 46 of 161), by CiteScore 2025.
Drug Design, Development and Therapy is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 6.9, which places it in quartile Q1 at the 75th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 1.309, quartile Q1, with an H-index of 121.
The publisher lists an article processing charge of about US$2,836 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Drug Design, Development and Therapy is published by Dove Medical Press Ltd. Its ISSN is 1177-8881.
Yes — indexed in the Science Citation Index Expanded.
Yes — it is an open-access journal, listed in DOAJ.
Drug Design, Development and Therapy has an h-index of 132 and a 2-year mean of 4.54 citations per paper (OpenAlex). Its Scopus CiteScore is 6.9, quartile Q1. On 2-year citations it ranks #36 of 177 Scopus journals in Pharmaceutical Science.
Drug Design, Development and Therapy published 762 papers in 2025. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 93 research articles (2026), authors are most often from China (85.3%), Indonesia (2.7%) and Taiwan (2.2%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 108 retracted papers are recorded (18.2 per 1,000 papers). The Problematic Paper Screener flags 4 of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.